139
Participants
Start Date
February 19, 2019
Primary Completion Date
February 2, 2021
Study Completion Date
August 31, 2023
Ravulizumab OBDS
The ravulizumab OBDS is a biological-device combination product consisting of a prefilled cartridge containing ravulizumab SC and an on-body injector.
Ravulizumab
Administered by IV infusion. Ravulizumab IV doses will be based on participant body weight.
Research Site, Rome
Research Site, Vienna
Research Site, Brussels
Research Site, Antwerp
Research Site, Liverpool
Research Site, Leuven
Research Site, Parkville
Research Site, Hasselt
Research Site, Nice
Research Site, Badalona
Research Site, Donostia / San Sebastian
Research Site, Milan
Research Site, Madrid
Research Site, Majadahonda
Research Site, Brest
Research Site, Montpellier
Research Site, Istanbul
Research Site, Istanbul
Research Site, Istanbul
Research Site, Las Palmas de Gran Canaria
Research Site, Rennes
Research Site, Izmir
Research Site, Tours
Research Site, Seville
Research Site, Nantes
Research Site, Lille
Research Site, Strasbourg
Research Site, Pierre-Bénite
Research Site, Paris
Research Site, Uppsala
Research Site, Amiens
Research Site, Poitiers
Research Site, Los Angeles
Research Site, Catania
Research Site, Moscow
Research Site, Moscow
Research Site, Saint Petersburg
Research Site, Yekaterinburg
Research Site, Rio de de Janeiro
Research Site, Salvador
Research Site, Botucatu
Research Site, Ribeirão Preto
Research Site, São Paulo
Research Site, São Paulo
Research Site, Toronto
Research Site, Helsinki
Research Site, Pessac
Research Site, Roma
Research Site, Maastricht
Research Site, Barcelona
Research Site, Adana
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY